Search results
Results from the WOW.Com Content Network
Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. [76] Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects ...
In general, pure beta-adrenergic agonists have the opposite function of beta blockers: beta-adrenoreceptor agonist ligands mimic the actions of both epinephrine- and norepinephrine- signaling, in the heart and lungs, and in smooth muscle tissue; epinephrine expresses the higher affinity.
The combination of beta blockers and antihypertensive drugs will work on different mechanism to lower blood pressure. [17] For example, the co-administration of beta-1 blocker atenolol and ACE inhibitor lisinopril could produce a 50% larger reduction in blood pressure than using either drug alone. [18]
beta-blockers, calcium channel blockers, and renin-angiotensin system-acting agents, which all help lower blood pressure. They also examined the combination use of these medications.
Anti-adrenergics: See also alpha blocker and beta blocker. Clonidine (α-receptor agonist, α 2 > α 1, giving negative feedback) Methyldopa (α 2 agonist, giving negative feedback) Propranolol (β-receptor antagonist) Metoprolol (β-receptor antagonist) Atenolol (β 1 antagonist) Prazosin (α 1 antagonist) Oxymetazoline (partial α2 adrenergic ...
The β 3 (beta 3) adrenergic receptor agonist or β 3-adrenoceptor agonist, also known as β 3-AR agonist, are a class of medicine that bind selectively to β 3-adrenergic receptors. β 3 -AR agonists for the treatment of obesity and type 2 diabetes have been in developmental stages within many large pharmaceutical companies since the early ...
Additionally, beta 1 blockers can affect beta 2 receptors, particularly at high doses, and hence should not be administered to patients with peripheral vascular disease or diabetes mellitus as they may cause vasoconstriction or a delayed hypoglycaemic response, respectively. [4]
Antinicotinic agents are classified into ganglionic blockers and neuromuscular blockers. Ganglionic blockers are of little clinical use as they act at all autonomic ganglions. [1] [2] They act by: Interfering acetylcholine release; Prolonged depolarization (depolarisation block), i.e. stimulation then block stimulation